Regulus Therapeutics this week announced that it has selected its first drug candidate, RG-101 for the treatment of hepatitis C. However, the company said it will develop the compound on its own despite an ongoing collaboration on the disease with GlaxoSmithKline.
Benitec Biopharma this week announced that the University of California, San Diego, has been selected as another site of the company’s phase I/II trial of the expressed RNAi-based hepatitis C treatment TT-034.
Benitec Biopharma announced last week that it has selected the Duke Clinical Research Unit as a site for its upcoming phase I/II trial for the expressed RNAi-based hepatitis C infection treatment TT-034.
NEW YORK (GenomeWeb News) – The US Food and Drug Administration approved Roche's next-generation viral load test for managing patients with chronic hepatitis C virus infection, the company announced today.
Health management services and diagnostics firm Alere recently updated investors on the progress of a pair of nucleic acid testing platforms that are currently under development at the company and represent the firm's entrée into molecular diagnostics.
Officials from Regulus Therapeutics this week said that the company continues to plan on filing two investigational new drug applications in 2014, one of which is for a microRNA-122-targeting hepatitis C treatment, but fell short of promising the goal would be met.
Santaris Pharma this week announced that the US Patent and Trademark Office has accepted its request to re-examine a patent exclusively licensed by rival Regulus Therapeutics covering the use of microRNA-122 inhibitors to treat hepatitis C infection.
Though not defined by any one major breakthrough as in years past, the RNAi therapeutics field made steady progress in 2012, particularly in terms of product and technology development, according to industry insiders.